<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:39:54Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6988171" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6988171</identifier>
        <datestamp>2020-02-03</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6988171</article-id>
              <article-id pub-id-type="pmcid">PMC6988171</article-id>
              <article-id pub-id-type="pmc-uid">6988171</article-id>
              <article-id pub-id-type="pmid">31852424</article-id>
              <article-id pub-id-type="pmid">31852424</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.118.011521</article-id>
              <article-id pub-id-type="publisher-id">JAH34641</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Heart Failure</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction</article-title>
                <alt-title alt-title-type="left-running-head">McDiarmid etÂ al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah34641-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>McDiarmid</surname>
                    <given-names>Adam K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34641-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>adam.mcdiarmid@nuth.nhs.uk</email>
                  </address>
                </contrib>
                <contrib id="jah34641-cr-0002" contrib-type="author">
                  <name>
                    <surname>Swoboda</surname>
                    <given-names>Peter P.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0003" contrib-type="author">
                  <name>
                    <surname>Erhayiem</surname>
                    <given-names>Bara</given-names>
                  </name>
                  <degrees>BMBS</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0004" contrib-type="author">
                  <name>
                    <surname>Bounford</surname>
                    <given-names>Katrina A.</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0005" contrib-type="author">
                  <name>
                    <surname>Bijsterveld</surname>
                    <given-names>Petra</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0006" contrib-type="author">
                  <name>
                    <surname>Tyndall</surname>
                    <given-names>Keith</given-names>
                  </name>
                  <degrees>RN</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0007" contrib-type="author">
                  <name>
                    <surname>Fent</surname>
                    <given-names>Graham J.</given-names>
                  </name>
                  <degrees>MBChB</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0008" contrib-type="author">
                  <name>
                    <surname>Garg</surname>
                    <given-names>Pankaj</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0009" contrib-type="author">
                  <name>
                    <surname>Dobson</surname>
                    <given-names>Laura E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0010" contrib-type="author">
                  <name>
                    <surname>Musa</surname>
                    <given-names>Tarique A.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0011" contrib-type="author">
                  <name>
                    <surname>Foley</surname>
                    <given-names>James R. J.</given-names>
                  </name>
                  <degrees>MBChB</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0012" contrib-type="author">
                  <name>
                    <surname>Witte</surname>
                    <given-names>Klaus K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0013" contrib-type="author">
                  <name>
                    <surname>Kearney</surname>
                    <given-names>Mark T.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0014" contrib-type="author">
                  <name>
                    <surname>Greenwood</surname>
                    <given-names>John P.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34641-cr-0015" contrib-type="author">
                  <name>
                    <surname>Plein</surname>
                    <given-names>Sven</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34641-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah34641-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Multidisciplinary Cardiovascular Research Centre and Leeds Institute of Cardiovascular and Metabolic Medicine</named-content>
                <institution>University of Leeds</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34641-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Cardiology</named-content>
                <institution>Freeman Hospital</institution>
                <city>NewcastleâuponâTyne</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34641-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Leeds Teaching Hospitals NHS Trust</institution>
                <city>Leeds</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Adam K. McDiarmid, MD, Multidisciplinary Cardiovascular Research Centre and Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Clarendon Way, Leeds, United Kingdom, and Division of Imaging Sciences and Biomedical Engineering, LS2 9JT. Eâmail: <email>adam.mcdiarmid@nuth.nhs.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>12</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>07</day>
                <month>1</month>
                <year>2020</year>
              </pub-date>
              <volume>9</volume>
              <issue>1</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v9.1</issue-id>
              <elocation-id>e011521</elocation-id>
              <history>
                <date date-type="received">
                  <day>02</day>
                  <month>2</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>6</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
                <copyright-statement content-type="article-copyright">Â© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-9-e011521.pdf"/>
              <abstract id="jah34641-abs-0001">
                <sec id="jah34641-sec-0001">
                  <title>Background</title>
                  <p>Spironolactone may have prognostic benefit in selected patients with heart failure with preserved ejection fraction. This study assessed the myocardial tissue effects of spironolactone in heart failure with preserved ejection fraction.</p>
                </sec>
                <sec id="jah34641-sec-0002">
                  <title>Methods and Results</title>
                  <p>A 1:1 randomized controlled study of 6Â months of spironolactone versus control in heart failure with preserved ejection fraction. The primary outcome was change in myocardial extracellular volume fraction by cardiovascular magnetic resonance as a surrogate of diffuse fibrosis. Of 55 randomized patients, 40 (20 women; age, 75.2Â±5.9Â years) completed followâup (19 treatment, 21 control). A significant change in extracellular volume over the study period was not seen (treatment, 28.7Â±3.7% versus 27.7Â±3.4% [<italic>P</italic>=0.14]; controls, 27.6Â±3.4% versus 28.3Â±4.4% [<italic>P</italic>=0.14]); however, the rate of extracellular volume expansion was decreased by spironolactone (â1.0Â±2.4% versus 0.8Â±2.2%). Indexed left ventricular mass decreased with treatment (104.4Â±26.6 versus 94.0Â±20.6Â g/m<sup>2</sup>; <italic>P</italic>=0.001) but not in controls (101.4Â±29.4 versus 104.0Â±32.8Â g/m<sup>2</sup>; <italic>P</italic>=0.111). Extracellular mass decreased by 13.8% (15.1Â±4.8 versus 13.0Â±3.4Â g/m<sup>2</sup>; <italic>P</italic>=0.003), and cellular mass decreased by 8.3% (37.6Â±10.0 versus 34.3Â±7.9Â g/m<sup>2</sup>; <italic>P</italic>=0.001) with spironolactone, but was static in controls.</p>
                </sec>
                <sec id="jah34641-sec-0003">
                  <title>Conclusions</title>
                  <p>Spironolactone did not lead to significant change in extracellular volume. However, spironolactone did decrease rate of extracellular expansion, with a decrease in the mass of both cellular and extracellular myocardial compartments. These data point to the mechanism of action of spironolactone in heart failure with preserved ejection fraction, including a direct tissue effect with a reduction in rate of myocardial fibrosis.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah34641-kwd-0001">cardiovascular magnetic resonance</kwd>
                <kwd id="jah34641-kwd-0002">extracellular volume</kwd>
                <kwd id="jah34641-kwd-0003">heart failure</kwd>
                <kwd id="jah34641-kwd-0004">heart failure with preserved ejection fraction</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Remodeling</kwd>
                <kwd>Heart Failure</kwd>
                <kwd>Magnetic Resonance Imaging (MRI)</kwd>
                <kwd>Fibrosis</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>British Heart Foundation </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100000274</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>PG/14/10/30641</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>BHF Clinical Fellowship</funding-source>
                  <award-id>FS/12/88/29474</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>BHF Personal Chair</funding-source>
                  <award-id>CH/16/2/32089</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>Program Grant</funding-source>
                  <award-id>RG/16/1/32092</award-id>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>NIHR Leeds Clinical Research Facility</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <page-count count="10"/>
                <word-count count="6978"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>07 January 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.4 mode:remove_FC converted:06.01.2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah34641-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2020</year>;<volume>9</volume>:<elocation-id>e011521</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.118.011521</pub-id>.)<pub-id pub-id-type="pmid">31852424</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body id="jah34641-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="jah34641-blkfxd-0001" orientation="portrait">
                <sec id="jah34641-sec-0005">
                  <title>Clinical Perspective</title>
                  <sec id="jah34641-sec-0006">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah34641-list-0001">
                        <list-item>
                          <p>In a randomized controlled study of 6Â months of spironolactone versus control in heart failure with preserved ejection fraction, spironolactone did not lead to a significant change in extracellular volume.</p>
                        </list-item>
                        <list-item>
                          <p>Spironolactone did, however, change rate of extracellular expansion, with a decrease in the mass of both cellular and extracellular myocardial compartments.</p>
                        </list-item>
                        <list-item>
                          <p>This study, using a noninvasive assessment of myocardial fibrosis, suggests that spironolactone administration in heart failure with preserved ejection fraction may lead to a relative decrease in diffuse myocardial fibrosis, a key pathophysiological feature of the disease.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah34641-sec-0007">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah34641-list-0002">
                        <list-item>
                          <p>Cardiovascular magnetic resonance fibrosis quantification, as part of a comprehensive noninvasive assessment, has potential as a new outcome measure in clinical studies where both conventional outcomes and the mode of action of an agent are to be established.</p>
                        </list-item>
                        <list-item>
                          <p>This study adds to the literature about the use of aldosterone antagonists in heart failure with preserved ejection fraction, suggesting it has potential as a true diseaseâmodifying agent in selected patients.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec id="jah34641-sec-0008">
              <title>Introduction</title>
              <p>In contrast to heart failure with reduced ejection fraction, treatment of heart failure with preserved ejection fraction (HFâPEF) lacks strong evidence for any specific diseaseâmodifying therapies.<xref rid="jah34641-bib-0001" ref-type="ref">1</xref> Despite several shared clinical and pathophysiological abnormalities, including myocardial fibrosis and neurohormonal activation,<xref rid="jah34641-bib-0002" ref-type="ref">2</xref> medications with clear benefit in heart failure with reduced ejection fraction, including angiotensinâconverting enzyme inhibition,<xref rid="jah34641-bib-0003" ref-type="ref">3</xref> angiotensin receptor blockade,<xref rid="jah34641-bib-0004" ref-type="ref">4</xref> and Î² blockade,<xref rid="jah34641-bib-0005" ref-type="ref">5</xref> have failed to demonstrate prognostic benefit in HFâPEF. Treatment with mineralocorticoid antagonist (MRA) has been tested in the recent randomized, doubleâblind TOPCAT (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function)<xref rid="jah34641-bib-0006" ref-type="ref">6</xref> trial. In the TOPCAT trial, 3445 patients with symptomatic heart failure and a left ventricular (LV) ejection fraction of â¥45% were assigned to receive either spironolactone or placebo. In the primary analysis, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. However, subgroup analysis of the study demonstrated a clinical benefit of MRA administration in selected patients.<xref rid="jah34641-bib-0007" ref-type="ref">7</xref> These patients tended to be an older group, many with atrial fibrillation and elevated heart failure biomarkers.<xref rid="jah34641-bib-0007" ref-type="ref">7</xref> Further randomized controlled studies have demonstrated that MRA administration in HFâPEF leads to improved tissue relaxation<xref rid="jah34641-bib-0008" ref-type="ref">8</xref> and positive changes in markers of collagen turnover,<xref rid="jah34641-bib-0009" ref-type="ref">9</xref> suggesting MRAs may have diseaseâmodifying properties in this group.</p>
              <p>MRAs are established in the treatment of heart failure with reduced ejection fraction,<xref rid="jah34641-bib-0010" ref-type="ref">10</xref>, <xref rid="jah34641-bib-0011" ref-type="ref">11</xref> and they improve both survival and quality of life, caused, in part, by modulation of myocardial fibrosis.<xref rid="jah34641-bib-0012" ref-type="ref">12</xref> Myocardial fibrosis is a key mediator of myocardial stiffness and diastolic dysfunction in HFâPEF,<xref rid="jah34641-bib-0013" ref-type="ref">13</xref>, <xref rid="jah34641-bib-0014" ref-type="ref">14</xref> and it has been demonstrated both invasively and noninvasively. Furthermore, noninvasively measured myocardial fibrosis has been associated with increasing myocardial stiffness and adverse prognosis.<xref rid="jah34641-bib-0015" ref-type="ref">15</xref> Prior mechanistic and clinical studies in HFâPEF have demonstrated that cardiac relaxation improves with MRA administration, and these changes are associated with changes in circulating biomarkers of collagen turnover.<xref rid="jah34641-bib-0008" ref-type="ref">8</xref>, <xref rid="jah34641-bib-0009" ref-type="ref">9</xref> In addition, MRAs also have a potent blood pressureâlowering effect.<xref rid="jah34641-bib-0016" ref-type="ref">16</xref> Although the subgroup analysis of the TOPCAT trial has suggested a benefit of spironolactone in certain patients with HFâPEF, it is unclear whether this is mediated by changes in blood pressure, fibrosis, or both.</p>
              <p>Cardiovascular magnetic resonance (CMR) provides accurate and reproducible assessment of cardiac structure, function,<xref rid="jah34641-bib-0017" ref-type="ref">17</xref> and scar. CMR T1 and extracellular volume (ECV) mapping are histologically validated techniques<xref rid="jah34641-bib-0018" ref-type="ref">18</xref> that allow quantification of expansion of the extracellular space and diffuse fibrosis and thus allow investigation of the mode of action and mechanisms of MRAs in HFâPEF. ECV is now becoming established as an important prognostic marker in heart failure with both reduced and preserved ejection fraction.<xref rid="jah34641-bib-0019" ref-type="ref">19</xref> In addition, the use of ECV quantification to measure the tissue effects of therapeutic interventions will allow assessment of interventions in disease characterized by expansion of the myocardial interstitium.<xref rid="jah34641-bib-0020" ref-type="ref">20</xref>
</p>
              <p>In this randomized trial, we used CMR to determine if spironolactone has an antifibrotic effect on myocardium in a wellâphenotyped population of patients with HFâPEF. For the first time, we were using a CMRâderived measure of diffuse myocardial fibrosis as a primary end point.</p>
            </sec>
            <sec id="jah34641-sec-0009">
              <title>Methods</title>
              <sec id="jah34641-sec-0010">
                <title>Monitoring and Ethics</title>
                <p>The study was conducted in accordance with the Declaration of Helsinki and registered with EudraCT (2013â000867â10). Approval by the National Research Ethics Service (13/NE/0292), sponsor institution, and Medicines and Health Regulatory Authority was given. The data that form the findings of this study are available from the corresponding author on reasonable request. All subjects gave informed written consent.</p>
              </sec>
              <sec id="jah34641-sec-0011">
                <title>Participants</title>
                <p>Adults, aged 18 to 90 years, with a clinical diagnosis of HFâPEF, according to 2012 European Society of Cardiology<xref rid="jah34641-bib-0001" ref-type="ref">1</xref> criteria, under the care of the local heart failure service (Leeds Teaching Hospitals NHS Trust, Leeds, UK) were eligible to participate in the study. Study inclusion criteria were as follows: New York Heart Association heart failure symptoms class II to IV, physical signs consistent with heart failure, LV ejection fraction on clinical echocardiography of &gt;50%, and NTâproBNP (Nâterminal proâBâtype natriuretic peptide) &gt;400Â pg/L at routine clinic attendance. Study exclusion criteria were as follows: renal impairment with estimated glomerular filtration rate &lt;30Â mL/min per 1.73Â m<sup>2</sup>, serum potassium &gt;5.0Â mmol/L at enrollment, allergy to spironolactone, inability to comply with study drug monitoring, diabetes mellitus, uncontrolled hypertension (&gt;140Â mmÂ Hg systolic blood pressure despite medical therapy), pregnancy, breastfeeding, Addison disease, and any relative or absolute contraindication to CMR. Patients with diabetes mellitus were specifically excluded as this has been shown independently to be associated with extracellular fibrosis by CMR.<xref rid="jah34641-bib-0021" ref-type="ref">21</xref>
</p>
              </sec>
              <sec id="jah34641-sec-0012">
                <title>Study Procedure</title>
                <p>Patients meeting entry criteria under the care of the local heart failure service were approached. After written informed consent was obtained, patients underwent a baseline assessment, including the following: study echocardiography, CMR, blood sampling, and 24âhour blood pressure, all of which were repeated at study completion (FigureÂ <xref rid="jah34641-fig-0001" ref-type="fig">1</xref>). On completion of baseline assessment, patients underwent 1:1 randomization without stratification, using a randomized permuted block strategy, with a standard block size of 20 provided by a commercial online system ( <ext-link ext-link-type="uri" xlink:href="https://www.sealedenvelope.com">https://www.sealedenvelope.com</ext-link>). Patients were randomized to nonblinded spironolactone, 25Â mg orally once daily, for 6Â months or no intervention (control group) without up titration. The study drug was commenced in accordance with National Institute for Health and Care Excellence<xref rid="jah34641-bib-0022" ref-type="ref">22</xref> and British National Formulary<xref rid="jah34641-bib-0023" ref-type="ref">23</xref> guidance, as per use in heart failure with reduced ejection fraction. Serum potassium and renal function were measured at 1Â week, 1Â month, 2Â months, 3Â months, and 6Â months after commencement. Dose adjustment and study drug withdrawal were performed in accordance with British National Formulary guidance. Patients who failed to attend safety monitoring in accordance with the study protocol were withdrawn from the study by investigators. Safety followâup was continued for 1Â month after study completion.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah34641-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Study flowchart. <styled-content style="fixed-case" toggle="no">BP</styled-content> indicates blood pressure; CMR, cardiovascular magnetic resonance.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-9-e011521-g001"/>
                </fig>
              </sec>
              <sec id="jah34641-sec-0013">
                <title>Assessments</title>
                <sec id="jah34641-sec-0014">
                  <title>Cardiovascular magnetic resonance</title>
                  <p>All studies were performed on a 3âT Achieva TX system equipped with a 32âchannel cardiac phased array receiver coil and multitransmit technology (Philips Healthcare, Best, the Netherlands). The cardiac long and short axes were determined using standard scout views. Mid LV native (precontrast) T1 maps were generated using a previously described modified look locker inversion recovery sequence,<xref rid="jah34641-bib-0024" ref-type="ref">24</xref> briefly comprising the following: ECG (electrocardiogram)âtriggered 5b(3s)3b modified look locker inversion recovery, flip angle of 35Â°, and voxel size of 1.98Ã1.98Ã10Â mm<sup>3</sup>. LV mass and volumes were obtained from cine imaging covering the entire LV in the short axis. Right ventricular and atrial volumes were obtained from a transaxial cine stack covering the entire heart. A total of 0.15Â mmol/kg gadobutrol (Gadovist; Bayer) was delivered by power injector (Medrad Inc, Warrendale, PA) as a single bolus via a venous cannula placed in the antecubital fossa, followed by a 20âmL saline flush at 5Â mL/s. Late gadolinium enhancement imaging was performed to image the entire LV 7 to 10Â minutes after contrast administration. Postcontrast T1 maps were acquired using the same modified look locker inversion recovery scheme 15Â minutes after contrast administration.</p>
                </sec>
                <sec id="jah34641-sec-0015">
                  <title>Image Analysis</title>
                  <p>All image analysis was performed using cmr<sup>42</sup> software (Circle Cardiovascular Imaging Inc, Calgary, AB, Canada) by operators blinded to treatment allocation. Volumetric and mass analysis was performed in the standard manner from the shortâaxis stack (LV) or longâaxis cine images (right ventricle). T1 values were calculated from source images using manual motion correction with a region of interest in the mid inferoseptum, ensuring avoidance of the blood pool.<xref rid="jah34641-bib-0025" ref-type="ref">25</xref> ECV was calculated, as previously described, with offline analysis of source images to avoid mistriggering and partial volume artefact.<xref rid="jah34641-bib-0026" ref-type="ref">26</xref> The masses of the cellular and extracellular myocardial compartments were derived as follows: indexed extracellular mass=indexed LV massÃECV; indexed cellular mass=indexed LV massÃ(1âECV). CMR analysis was performed by 2 observers (A.K.M. and P.P.S.) blinded to subject data.</p>
                </sec>
                <sec id="jah34641-sec-0016">
                  <title>Echocardiography</title>
                  <p>All patients underwent echocardiography (Vivid e9; GE Medical Systems, Milwaukee, WI), including Doppler measurements of mitral inflow and tissue Doppler imaging of the lateral and medial mitral annulus for the assessment of diastolic function in accordance with national guidelines. Studies were performed by British Society of Echocardiographyâaccredited echocardiographers, blinded to study information.</p>
                </sec>
                <sec id="jah34641-sec-0017">
                  <title>24 Hour Blood Pressure</title>
                  <p>Ambulatory blood pressure at 24 hours was performed on standard clinical equipment (DelMar Reynolds NIBP; Sentinel Space Lab 7.0.0737), with analysis performed by institute physiologists, blinded to study information.</p>
                </sec>
                <sec id="jah34641-sec-0018">
                  <title>Biomarkers</title>
                  <p>Blood (20 mL) was drawn from each subject while supine at the time of CMR. Full blood count was measured at that time. Serum was stored at â70Â°C and tested in one batch for NTâproBNP, procollagen type I Nâterminal peptide, procollagen type III Nâterminal peptide, highâsensitivity CRP (Câreactive protein), and matrix metallopeptidase 3.</p>
                </sec>
              </sec>
              <sec id="jah34641-sec-0019">
                <title>Study End Points</title>
                <p>The prespecified primary outcome was difference in final myocardial ECV (%) after 6Â months of treatment with spironolactone between treatment groups. Prespecified secondary outcomes included the relationship between change in myocardial tissue composition and echocardiographic measures of myocardial tissue relaxation, LV geometry, blood pressure, and circulating biomarkers.</p>
              </sec>
              <sec id="jah34641-sec-0020">
                <title>Statistical Analysis</title>
                <p>Statistical analysis was performed using IBM SPSS Statistics 24.0 (IBM Corp, Armonk, NY). Unless otherwise stated, the results are presented as meanÂ±SD. Normality of distribution was determined with KolmogorovâSmirnov testing. Differences between groups were assessed using the Ï<sup>2</sup> test and paired or independent <italic>t</italic> test, where appropriate. Correlation was assessed with Spearman correlation coefficient. Analysis was conducted as a complete case analysis. To detect a change in ECV of 1.5% on treatment with spironolactone (interstudy SD, 1.95%<xref rid="jah34641-bib-0024" ref-type="ref">24</xref>; significance, 5%; power, 90%), a sample size of 20 was required in each arm. Significance for all tests was defined as <italic>P</italic>&lt;0.05.</p>
              </sec>
            </sec>
            <sec id="jah34641-sec-0021">
              <title>Results</title>
              <sec id="jah34641-sec-0022">
                <title>Study Participant Demographics and Baseline Characteristics</title>
                <p>A total of 55 subjects were recruited, with 40 completing the followâup period (19 in the treatment group and 21 in the control group). Of those who did not complete followâup, 8 (5 women and 3 men) were in the treatment group, 3 (2 women and 1 man) were in the monitoring group, and 4 dropped out before randomization (3 women and 1 man). Reasons for study dropout were as follows: deterioration in renal function (n=3), inability to tolerate CMR (n=1), protocol breach (n=3), and withdrawal of consent (n=8).</p>
                <p>Of those who completed followâup, the mean age was 75.1Â±7.3Â years, and 20 were women (50%). Subject demographics in the active treatment and monitoring groups were similar between the 2 groups and can be seen in TableÂ <xref rid="jah34641-tbl-0001" ref-type="table">1</xref>. Baseline characteristics were similar between groups, with atrial fibrillation (89% spironolactone versus 71% control group; <italic>P</italic>=0.15) and hypertension (79% spironolactone versus 62% control group; <italic>P</italic>=0.15) common in both groups. Prerandomization medical therapy did not differ significantly between groups, with widespread prescription of angiotensinâconverting enzyme inhibitors, Î² blockers, and diuretics. NTâproBNP was elevated as mandated by study protocol and not significantly different between groups (spironolactone versus control, 1737.2Â±1238.7 versus 1699Â±1548.0Â pg/L; <italic>P</italic>=0.932). Cardiac geometry by CMR was similar between groups, and no differences were seen in measures of echocardiographic tissue relaxation. Native T1 at baseline was lower in the treatment group compared with controls (1229Â±52.3 versus 1266.7Â±59.4Â ms; <italic>P</italic>=0.041), although ECV did not differ (28.7Â±3.7% versus 27.3Â±3.1%; <italic>P</italic>=0.31) (TableÂ <xref rid="jah34641-tbl-0002" ref-type="table">2</xref>).</p>
                <table-wrap id="jah34641-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Spironolactone (n=19)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Control (n=21)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sex (male/female ratio)</td>
                        <td align="left" rowspan="1" colspan="1">10:9</td>
                        <td align="left" rowspan="1" colspan="1">10:11</td>
                        <td align="left" rowspan="1" colspan="1">0.75</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1">76.4Â±5.4</td>
                        <td align="left" rowspan="1" colspan="1">74.0Â±8.8</td>
                        <td align="left" rowspan="1" colspan="1">0.295</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">29.8Â±5.3</td>
                        <td align="left" rowspan="1" colspan="1">29.1Â±7.1</td>
                        <td align="left" rowspan="1" colspan="1">0.71</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Comorbidities</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension </td>
                        <td align="left" rowspan="1" colspan="1">15 (79)</td>
                        <td align="left" rowspan="1" colspan="1">13 (62)</td>
                        <td align="left" rowspan="1" colspan="1">0.240</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Atrial fibrillation </td>
                        <td align="left" rowspan="1" colspan="1">17 (89)</td>
                        <td align="left" rowspan="1" colspan="1">15 (71)</td>
                        <td align="left" rowspan="1" colspan="1">0.154</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Heart rate/min (sinus)</td>
                        <td align="left" rowspan="1" colspan="1">77Â±10.6</td>
                        <td align="left" rowspan="1" colspan="1">74.5Â±12.5</td>
                        <td align="left" rowspan="1" colspan="1">0.541</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Heart rate/min (atrial fibrillation)</td>
                        <td align="left" rowspan="1" colspan="1">77Â±19.8</td>
                        <td align="left" rowspan="1" colspan="1">73.8Â±7.5</td>
                        <td align="left" rowspan="1" colspan="1">0.745</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ischemic heart disease </td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">1 (5)</td>
                        <td align="left" rowspan="1" colspan="1">0.335</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cerebrovascular disease </td>
                        <td align="left" rowspan="1" colspan="1">3 (16)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">0.058</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Medications</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE inhibitor/ARB</td>
                        <td align="left" rowspan="1" colspan="1">11 (58)</td>
                        <td align="left" rowspan="1" colspan="1">12 (57)</td>
                        <td align="left" rowspan="1" colspan="1">0.962</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Î² Blocker</td>
                        <td align="left" rowspan="1" colspan="1">10 (53)</td>
                        <td align="left" rowspan="1" colspan="1">14 (67)</td>
                        <td align="left" rowspan="1" colspan="1">0.366</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcium channel blocker</td>
                        <td align="left" rowspan="1" colspan="1">11 (58)</td>
                        <td align="left" rowspan="1" colspan="1">12 (57)</td>
                        <td align="left" rowspan="1" colspan="1">0.962</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Digoxin</td>
                        <td align="left" rowspan="1" colspan="1">3 (16)</td>
                        <td align="left" rowspan="1" colspan="1">9 (43)</td>
                        <td align="left" rowspan="1" colspan="1">0.062</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diuretic</td>
                        <td align="left" rowspan="1" colspan="1">12 (63)</td>
                        <td align="left" rowspan="1" colspan="1">12 (57)</td>
                        <td align="left" rowspan="1" colspan="1">0.698</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">NYHA status</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">II</td>
                        <td align="left" rowspan="1" colspan="1">14</td>
                        <td align="left" rowspan="1" colspan="1">17</td>
                        <td align="left" rowspan="3" colspan="1">0.583</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">III</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">IV</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34641-ntgp-0001">
                    <fn id="jah34641-note-0001">
                      <p>Data are given as meanÂ±SD, number (percentage), or number. ACE indicates angiotensinâconverting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; NYHA, New York Heart Association.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="jah34641-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Baseline and Intervention Effect (Multimodality Imaging)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1">Variable</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Spironolactone</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Control</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Change Over Study Period</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Completion</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Completion</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Intervention</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Control</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">CMR volumetric</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LVEDV, mL</td>
                        <td align="left" rowspan="1" colspan="1">142.5Â±26.5</td>
                        <td align="left" rowspan="1" colspan="1">129.8Â±21.6</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1">138.9Â±35.3</td>
                        <td align="left" rowspan="1" colspan="1">136.9Â±38.2</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                        <td align="left" rowspan="1" colspan="1">â12.6Â±14.3</td>
                        <td align="left" rowspan="1" colspan="1">â2.00Â±11.7</td>
                        <td align="left" rowspan="1" colspan="1">0.014</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed LVEDV, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">71.8Â±14.0</td>
                        <td align="left" rowspan="1" colspan="1">65.4Â±11.2</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1">71.8Â±18.5</td>
                        <td align="left" rowspan="1" colspan="1">70.7Â±19.5</td>
                        <td align="left" rowspan="1" colspan="1">0.43</td>
                        <td align="left" rowspan="1" colspan="1">â6.4Â±7.4</td>
                        <td align="left" rowspan="1" colspan="1">â3.40Â±11.3</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LV mass, g</td>
                        <td align="left" rowspan="1" colspan="1">104.4Â±26.2</td>
                        <td align="left" rowspan="1" colspan="1">94.0Â±20.6</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1">101.4Â±29.4</td>
                        <td align="left" rowspan="1" colspan="1">104.0Â±32.8</td>
                        <td align="left" rowspan="1" colspan="1">0.11</td>
                        <td align="left" rowspan="1" colspan="1">â10.5Â±10.9</td>
                        <td align="left" rowspan="1" colspan="1">2.6Â±6.9</td>
                        <td align="left" rowspan="1" colspan="1">0.00</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed LV mass, g/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">52.7Â±14.1</td>
                        <td align="left" rowspan="1" colspan="1">47.3Â±10.8</td>
                        <td align="left" rowspan="1" colspan="1">&gt;0.001</td>
                        <td align="left" rowspan="1" colspan="1">52.1Â±14.0</td>
                        <td align="left" rowspan="1" colspan="1">53.3Â±15.1</td>
                        <td align="left" rowspan="1" colspan="1">0.15</td>
                        <td align="left" rowspan="1" colspan="1">â5.4Â±5.5</td>
                        <td align="left" rowspan="1" colspan="1">1.1Â±3.7</td>
                        <td align="left" rowspan="1" colspan="1">0.00</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LVEF, %</td>
                        <td align="left" rowspan="1" colspan="1">53.5Â±5.5</td>
                        <td align="left" rowspan="1" colspan="1">53.8Â±6.6</td>
                        <td align="left" rowspan="1" colspan="1">0.85</td>
                        <td align="left" rowspan="1" colspan="1">54.8Â±5.2</td>
                        <td align="left" rowspan="1" colspan="1">58.2Â±6.4</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1">0.3Â±6.7</td>
                        <td align="left" rowspan="1" colspan="1">3.5Â±4.0</td>
                        <td align="left" rowspan="1" colspan="1">0.084</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">RVEDV, mL</td>
                        <td align="left" rowspan="1" colspan="1">140.0Â±26.6</td>
                        <td align="left" rowspan="1" colspan="1">137.7Â±19.4</td>
                        <td align="left" rowspan="1" colspan="1">0.60</td>
                        <td align="left" rowspan="1" colspan="1">153.0Â±43.4</td>
                        <td align="left" rowspan="1" colspan="1">155.5Â±43.7</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                        <td align="left" rowspan="1" colspan="1">â2.22Â±17.5</td>
                        <td align="left" rowspan="1" colspan="1">2.50Â±15.9</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed RVEDV, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">74.4Â±14.6</td>
                        <td align="left" rowspan="1" colspan="1">73.31Â±11.3</td>
                        <td align="left" rowspan="1" colspan="1">0.64</td>
                        <td align="left" rowspan="1" colspan="1">76.3Â±20.1</td>
                        <td align="left" rowspan="1" colspan="1">78.9Â±18.9</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                        <td align="left" rowspan="1" colspan="1">â1.07Â±9.6</td>
                        <td align="left" rowspan="1" colspan="1">1.46Â±8.5</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">RVEF, %</td>
                        <td align="left" rowspan="1" colspan="1">48.4Â±5.7</td>
                        <td align="left" rowspan="1" colspan="1">47.1Â±7.0</td>
                        <td align="left" rowspan="1" colspan="1">0.26</td>
                        <td align="left" rowspan="1" colspan="1">46.5Â±6.6</td>
                        <td align="left" rowspan="1" colspan="1">44.8Â±15.8</td>
                        <td align="left" rowspan="1" colspan="1">0.64</td>
                        <td align="left" rowspan="1" colspan="1">â1.3Â±4.8</td>
                        <td align="left" rowspan="1" colspan="1">â1.8Â±16.4</td>
                        <td align="left" rowspan="1" colspan="1">0.91</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left atrial volume, mL</td>
                        <td align="left" rowspan="1" colspan="1">145.6Â±32.2</td>
                        <td align="left" rowspan="1" colspan="1">142.4Â±30.7</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                        <td align="left" rowspan="1" colspan="1">133.7Â±36.8</td>
                        <td align="left" rowspan="1" colspan="1">135.0Â±36.8</td>
                        <td align="left" rowspan="1" colspan="1">0.70</td>
                        <td align="left" rowspan="1" colspan="1">â3.3Â±17.4</td>
                        <td align="left" rowspan="1" colspan="1">1.4Â±14.9</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed left atrial volume, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">73.6Â±16.7</td>
                        <td align="left" rowspan="1" colspan="1">72.0Â±15.7</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                        <td align="left" rowspan="1" colspan="1">69.1Â±18.5</td>
                        <td align="left" rowspan="1" colspan="1">69.9Â±18.4</td>
                        <td align="left" rowspan="1" colspan="1">0.67</td>
                        <td align="left" rowspan="1" colspan="1">â1.6Â±8.9</td>
                        <td align="left" rowspan="1" colspan="1">0.8Â±7.6</td>
                        <td align="left" rowspan="1" colspan="1">0.38</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Right atrial volume, mL</td>
                        <td align="left" rowspan="1" colspan="1">157.6Â±40.3</td>
                        <td align="left" rowspan="1" colspan="1">148.5Â±35.2</td>
                        <td align="left" rowspan="1" colspan="1">0.11</td>
                        <td align="left" rowspan="1" colspan="1">153.1Â±49.9</td>
                        <td align="left" rowspan="1" colspan="1">146.6Â±45.2</td>
                        <td align="left" rowspan="1" colspan="1">0.17</td>
                        <td align="left" rowspan="1" colspan="1">â9.1Â±23.1</td>
                        <td align="left" rowspan="1" colspan="1">â6.5Â±20.0</td>
                        <td align="left" rowspan="1" colspan="1">0.72</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed right atrial volume, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">79.6Â±20.3</td>
                        <td align="left" rowspan="1" colspan="1">74.6Â±15.8</td>
                        <td align="left" rowspan="1" colspan="1">0.080</td>
                        <td align="left" rowspan="1" colspan="1">79.0Â±24.8</td>
                        <td align="left" rowspan="1" colspan="1">75.6Â±21.9</td>
                        <td align="left" rowspan="1" colspan="1">0.19</td>
                        <td align="left" rowspan="1" colspan="1">â5.0Â±11.4</td>
                        <td align="left" rowspan="1" colspan="1">â3.4Â±10.6</td>
                        <td align="left" rowspan="1" colspan="1">0.65</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Echo tissue relaxation</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lateral Eâ²</td>
                        <td align="left" rowspan="1" colspan="1">11.22Â±2.42</td>
                        <td align="left" rowspan="1" colspan="1">11.09Â±2.59</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                        <td align="left" rowspan="1" colspan="1">10.21Â±3.39</td>
                        <td align="left" rowspan="1" colspan="1">10.99Â±4.48</td>
                        <td align="left" rowspan="1" colspan="1">0.24</td>
                        <td align="left" rowspan="1" colspan="1">â0.12Â±3.043</td>
                        <td align="left" rowspan="1" colspan="1">0.83Â±3.07</td>
                        <td align="left" rowspan="1" colspan="1">0.34</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Septal Eâ²</td>
                        <td align="left" rowspan="1" colspan="1">8.65Â±2.00</td>
                        <td align="left" rowspan="1" colspan="1">8.14Â±1.72</td>
                        <td align="left" rowspan="1" colspan="1">0.21</td>
                        <td align="left" rowspan="1" colspan="1">8.09Â±3.24</td>
                        <td align="left" rowspan="1" colspan="1">7.89Â±2.80</td>
                        <td align="left" rowspan="1" colspan="1">0.71</td>
                        <td align="left" rowspan="1" colspan="1">â0.51Â±1.72</td>
                        <td align="left" rowspan="1" colspan="1">â0.24Â±2.48</td>
                        <td align="left" rowspan="1" colspan="1">0.70</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean Eâ²</td>
                        <td align="left" rowspan="1" colspan="1">9.89Â±1.87</td>
                        <td align="left" rowspan="1" colspan="1">9.15Â±2.81</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                        <td align="left" rowspan="1" colspan="1">9.15Â±3.36</td>
                        <td align="left" rowspan="1" colspan="1">9.44Â±3.49</td>
                        <td align="left" rowspan="1" colspan="1">0.58</td>
                        <td align="left" rowspan="1" colspan="1">â0.32Â±1.86</td>
                        <td align="left" rowspan="1" colspan="1">0.29Â±2.43</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">CMR tissue characterization</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Native T1, ms</td>
                        <td align="left" rowspan="1" colspan="1">1229Â±52</td>
                        <td align="left" rowspan="1" colspan="1">1207Â±87</td>
                        <td align="left" rowspan="1" colspan="1">0.31</td>
                        <td align="left" rowspan="1" colspan="1">1266Â±59</td>
                        <td align="left" rowspan="1" colspan="1">1241Â±71</td>
                        <td align="left" rowspan="1" colspan="1">0.018</td>
                        <td align="left" rowspan="1" colspan="1">1Â±107</td>
                        <td align="left" rowspan="1" colspan="1">â22Â±2</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ECV, %</td>
                        <td align="left" rowspan="1" colspan="1">28.7Â±3.7</td>
                        <td align="left" rowspan="1" colspan="1">27.7Â±3.4</td>
                        <td align="left" rowspan="1" colspan="1">0.14</td>
                        <td align="left" rowspan="1" colspan="1">27.6Â±3.4</td>
                        <td align="left" rowspan="1" colspan="1">28.3Â±4.4</td>
                        <td align="left" rowspan="1" colspan="1">0.14</td>
                        <td align="left" rowspan="1" colspan="1">â1.0Â±2.43</td>
                        <td align="left" rowspan="1" colspan="1">0.8Â±2.2</td>
                        <td align="left" rowspan="1" colspan="1">0.019</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed cellular mass, g</td>
                        <td align="left" rowspan="1" colspan="1">37.6Â±10.0</td>
                        <td align="left" rowspan="1" colspan="1">34.3Â±7.9</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1">37.5Â±9.6</td>
                        <td align="left" rowspan="1" colspan="1">37.8Â±9.8</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                        <td align="left" rowspan="1" colspan="1">â3.3Â±3.7</td>
                        <td align="left" rowspan="1" colspan="1">1.1Â±5.3</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Indexed extracellular mass, g</td>
                        <td align="left" rowspan="1" colspan="1">15.1Â±4.8</td>
                        <td align="left" rowspan="1" colspan="1">13.0Â±3.4</td>
                        <td align="left" rowspan="1" colspan="1">0.002</td>
                        <td align="left" rowspan="1" colspan="1">14.4Â±4.8</td>
                        <td align="left" rowspan="1" colspan="1">15.0Â±5.9</td>
                        <td align="left" rowspan="1" colspan="1">0.091</td>
                        <td align="left" rowspan="1" colspan="1">â2.1Â±2.6</td>
                        <td align="left" rowspan="1" colspan="1">0.8Â±1.7</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34641-ntgp-0002">
                    <fn id="jah34641-note-0002">
                      <p>Data are given as meanÂ±SD. CMR indicates cardiovascular magnetic resonance; ECV, extracellular volume; LV, left ventricular; LVEDV, LV endâdiastolic volume; LVEF, LV ejection fraction; RVEDV, right ventricular endâdiastolic volume; RVEF, right ventricular ejection fraction.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah34641-sec-0023">
                <title>Intervention Effect</title>
                <p>A significant change in absolute ECV was not seen over the study period in either the treatment group (28.7Â±3.7% versus 27.7Â±3.4%; <italic>P</italic>=0.14) or controls (27.6Â±3.4% versus 28.3Â±4.4%; <italic>P</italic>=0.14). However, a significant difference was seen in rate of ECV (ÎECV) expansion between treatment and control groups (â1.0Â±2.4% versus 0.8Â±2.2%) (FigureÂ <xref rid="jah34641-fig-0002" ref-type="fig">2</xref>). In addition, over the study period, significant changes were seen after intervention in indexed LV mass (52.7Â±14.1 versus 47.3Â±10.8Â g/m<sup>2</sup>; <italic>P</italic>&lt;0.01) and LV volume (71.8Â±14.0 versus 65.4Â±11.2Â mL/m<sup>2</sup>; <italic>P</italic>&lt;0.01) but not in the control group (52.1Â±14.0 versus 53.3Â±15.1Â g/m<sup>2</sup> [<italic>P</italic>=0.15]; and 71.8Â±18.5 versus 70.7Â±19.5Â mL/m<sup>2</sup> [<italic>P</italic>=0.43], respectively) (TableÂ <xref rid="jah34641-tbl-0002" ref-type="table">2</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah34641-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Effect on myocardial fibrosis of spironolactone vs controls in heart failure with preserved ejection fraction. Significant change was not seen on intragroup analysis (<italic>P</italic>=0.135 and <italic>P</italic>=0.143, respectively); however, rate of change in extracellular volume (<styled-content style="fixed-case" toggle="no">ECV</styled-content>) differed significantly, with a relative decrease seen in extracellular volume after treatment (<italic>P</italic>=0.019). </p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JAH3-9-e011521-g002"/>
                </fig>
                <p>The mass of both myocardial compartments decreased significantly after MRA administration, with an 8.3% (74.5Â±19.4 versus 68.3Â±15.9Â g/m<sup>2</sup>; <italic>P</italic>&lt;0.01) reduction in cellular mass and a 13.8% (29.8Â±8.4 versus 25.7Â±5.9Â g/m<sup>2</sup>; <italic>P</italic>&lt;0.01) reduction in the extracellular mass seen. In the control group, no significant change was seen in either indexed cellular (73.3Â±20.5 versus 74.3Â±22.0Â g/m<sup>2</sup>; <italic>P</italic>=0.390) or extracellular mass (14.4Â±4.8 versus 15.0Â±5.9Â g/m<sup>2</sup>; <italic>P</italic>=0.091) over the study period.</p>
                <p>In the treatment group, significant change was seen in systolic (130.8Â±19.1 versus 120.2Â±13.5Â mmÂ Hg; <italic>P</italic>&lt;0.01) and diastolic blood pressure (76.8Â±8.0 versus 72.1Â±6.8Â mmÂ Hg; <italic>P</italic>=0.013), mean arterial pressure (94.2Â±10.4 versus 79.7Â±5.9Â mmÂ Hg; <italic>P</italic>&lt;0.01), and serum creatinine (97.4Â±27.2 versus 109.6Â±37.0Â mmol/L; <italic>P</italic>&lt;0.01), whereas no significant changes were seen in the control group.</p>
                <p>No changes were seen in echocardiographic measures of cardiac relaxation, circulating markers of collagen turnover, or heart failure severity (TableÂ <xref rid="jah34641-tbl-0003" ref-type="table">3</xref>).</p>
                <table-wrap id="jah34641-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Baseline and Intervention Effect (Blood Pressure and Serum)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1">Variable</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Spironolactone</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Control</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Change Over Study Period</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Completion</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Completion</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Intervention</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Control</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Blood pressure</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">130.8Â±19.1</td>
                        <td align="left" rowspan="1" colspan="1">120.2Â±13.5</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                        <td align="left" rowspan="1" colspan="1">129.6Â±9.9</td>
                        <td align="left" rowspan="1" colspan="1">130.5Â±13.1</td>
                        <td align="left" rowspan="1" colspan="1">0.625</td>
                        <td align="left" rowspan="1" colspan="1">â9.94Â±13.2</td>
                        <td align="left" rowspan="1" colspan="1">1.00Â±13.3</td>
                        <td align="left" rowspan="1" colspan="1">0.017</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">76.8Â±8.0</td>
                        <td align="left" rowspan="1" colspan="1">72.1Â±6.8</td>
                        <td align="left" rowspan="1" colspan="1">0.013</td>
                        <td align="left" rowspan="1" colspan="1">75.4Â±11.4</td>
                        <td align="left" rowspan="1" colspan="1">79.1Â±12.6</td>
                        <td align="left" rowspan="1" colspan="1">0.195</td>
                        <td align="left" rowspan="1" colspan="1">â4.33Â±6.7</td>
                        <td align="left" rowspan="1" colspan="1">2.84Â±11.1</td>
                        <td align="left" rowspan="1" colspan="1">0.023</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">MABP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">94.2Â±10.4</td>
                        <td align="left" rowspan="1" colspan="1">79.7Â±5.9</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                        <td align="left" rowspan="1" colspan="1">94.6Â±8.9</td>
                        <td align="left" rowspan="1" colspan="1">89.2Â±8.8</td>
                        <td align="left" rowspan="1" colspan="1">0.045</td>
                        <td align="left" rowspan="1" colspan="1">â5.47Â±6.9</td>
                        <td align="left" rowspan="1" colspan="1">0.89Â±10.0</td>
                        <td align="left" rowspan="1" colspan="1">0.035</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pulse pressure, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">52.1Â±19.0</td>
                        <td align="left" rowspan="1" colspan="1">38.7Â±18.6</td>
                        <td align="left" rowspan="1" colspan="1">0.004</td>
                        <td align="left" rowspan="1" colspan="1">54.2Â±11.2</td>
                        <td align="left" rowspan="1" colspan="1">50.2Â±21.1</td>
                        <td align="left" rowspan="1" colspan="1">0.353</td>
                        <td align="left" rowspan="1" colspan="1">â5.61Â±9.4</td>
                        <td align="left" rowspan="1" colspan="1">â1.84Â±10.2</td>
                        <td align="left" rowspan="1" colspan="1">0.252</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Laboratory</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">97.4Â±27.2</td>
                        <td align="left" rowspan="1" colspan="1">109.6Â±37.0</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                        <td align="left" rowspan="1" colspan="1">101.33Â±38.1</td>
                        <td align="left" rowspan="1" colspan="1">96.3Â±29.0</td>
                        <td align="left" rowspan="1" colspan="1">0.460</td>
                        <td align="left" rowspan="1" colspan="1">12.7Â±14.7</td>
                        <td align="left" rowspan="1" colspan="1">â5.1Â±30.7</td>
                        <td align="left" rowspan="1" colspan="1">0.027</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Potassium, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">4.11Â±0.4</td>
                        <td align="left" rowspan="1" colspan="1">4.31Â±0.4</td>
                        <td align="left" rowspan="1" colspan="1">0.056</td>
                        <td align="left" rowspan="1" colspan="1">4.06Â±0.22</td>
                        <td align="left" rowspan="1" colspan="1">4.10Â±0.43</td>
                        <td align="left" rowspan="1" colspan="1">0.673</td>
                        <td align="left" rowspan="1" colspan="1">0.26Â±0.35</td>
                        <td align="left" rowspan="1" colspan="1">0.04Â±0.46</td>
                        <td align="left" rowspan="1" colspan="1">0.097</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Serum biomarkers</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">NTâproBNP, pg/mL</td>
                        <td align="left" rowspan="1" colspan="1">1667Â±1246</td>
                        <td align="left" rowspan="1" colspan="1">1619Â±1169</td>
                        <td align="left" rowspan="1" colspan="1">0.753</td>
                        <td align="left" rowspan="1" colspan="1">1706Â±1588</td>
                        <td align="left" rowspan="1" colspan="1">1599Â±1496</td>
                        <td align="left" rowspan="1" colspan="1">0.494</td>
                        <td align="left" rowspan="1" colspan="1">â78Â±676</td>
                        <td align="left" rowspan="1" colspan="1">â107Â±685</td>
                        <td align="left" rowspan="1" colspan="1">0.895</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">P1NP</td>
                        <td align="left" rowspan="1" colspan="1">52.32Â±18.83</td>
                        <td align="left" rowspan="1" colspan="1">51.47Â±19.94</td>
                        <td align="left" rowspan="1" colspan="1">0.733</td>
                        <td align="left" rowspan="1" colspan="1">57.15Â±31.47</td>
                        <td align="left" rowspan="1" colspan="1">50.25Â±26.06</td>
                        <td align="left" rowspan="1" colspan="1">0.130</td>
                        <td align="left" rowspan="1" colspan="1">â1.72Â±10.16</td>
                        <td align="left" rowspan="1" colspan="1">â6.90Â±19.52</td>
                        <td align="left" rowspan="1" colspan="1">0.307</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">P3NP</td>
                        <td align="left" rowspan="1" colspan="1">9.816Â±3.22</td>
                        <td align="left" rowspan="1" colspan="1">9.02Â±2.94</td>
                        <td align="left" rowspan="1" colspan="1">0.223</td>
                        <td align="left" rowspan="1" colspan="1">10.0Â±3.70</td>
                        <td align="left" rowspan="1" colspan="1">8.39Â±2.93</td>
                        <td align="left" rowspan="1" colspan="1">0.013</td>
                        <td align="left" rowspan="1" colspan="1">â0.53Â±2.57</td>
                        <td align="left" rowspan="1" colspan="1">â1.61Â±2.70</td>
                        <td align="left" rowspan="1" colspan="1">0.208</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HSâCRP</td>
                        <td align="left" rowspan="1" colspan="1">4.55Â±3.33</td>
                        <td align="left" rowspan="1" colspan="1">4.09Â±3.13</td>
                        <td align="left" rowspan="1" colspan="1">0.560</td>
                        <td align="left" rowspan="1" colspan="1">5.30Â±3.91</td>
                        <td align="left" rowspan="1" colspan="1">5.06Â±3.60</td>
                        <td align="left" rowspan="1" colspan="1">0.629</td>
                        <td align="left" rowspan="1" colspan="1">â0.79Â±3.1</td>
                        <td align="left" rowspan="1" colspan="1">â0.25Â±2.29</td>
                        <td align="left" rowspan="1" colspan="1">0.536</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">MMP3</td>
                        <td align="left" rowspan="1" colspan="1">228.29Â±50.04</td>
                        <td align="left" rowspan="1" colspan="1">224.65Â±57.65</td>
                        <td align="left" rowspan="1" colspan="1">0.762</td>
                        <td align="left" rowspan="1" colspan="1">237.63Â±72.59</td>
                        <td align="left" rowspan="1" colspan="1">243.85Â±54.20</td>
                        <td align="left" rowspan="1" colspan="1">0.663</td>
                        <td align="left" rowspan="1" colspan="1">â3.64Â±51.64</td>
                        <td align="left" rowspan="1" colspan="1">6.21Â±64.28</td>
                        <td align="left" rowspan="1" colspan="1">0.599</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34641-ntgp-0003">
                    <fn id="jah34641-note-0004">
                      <p>Data are given as meanÂ±SD. HSâCRP indicates highâsensitivity Câreactive protein; MABP, mean arterial blood pressure; MMP3, matrix metallopeptidase 3; NTâproBNP, Nâterminal proâBâtype natriuretic peptide; P1NP, procollagen type I Nâterminal peptide; P3NP, procollagen type III Nâterminal peptide.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Correlations were determined between ÎECV, LV geometry and relaxation, systolic and diastolic blood pressure, mean arterial pressure, markers of collagen turnover, and heart failure severity across the whole study group. Significant correlations were seen between ÎECV and indexed LV mass (<italic>r</italic>=0.442; <italic>P</italic>&lt;0.01), LVEDVi (indexed Left Ventricular End Diastolic Volume) (<italic>r</italic>=0.401; <italic>P</italic>=0.011), and tissue relaxation (mean Eâ²; <italic>r</italic>=0.348; <italic>P</italic>=0.03), although not with change in blood pressure. Change in indexed LV mass correlated with change in all systolic, diastolic, and mean arterial blood pressure (<italic>r</italic>=0.468 [<italic>P</italic>=0.004], <italic>r</italic>=0.357 [<italic>P</italic>=0.032], and <italic>r</italic>=0.367 [<italic>P</italic>=0.03], respectively) (TableÂ <xref rid="jah34641-tbl-0004" ref-type="table">4</xref>).</p>
                <table-wrap id="jah34641-tbl-0004" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 4</label>
                  <caption>
                    <p>Correlation of Selected Imaging and Physiological Changes</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Change ECV</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <italic>R</italic>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Change Indexed LV Mass</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <italic>R</italic>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ECV, %</td>
                        <td align="left" rowspan="1" colspan="1">Â·Â·Â·</td>
                        <td align="left" rowspan="1" colspan="1">Â·Â·Â·</td>
                        <td align="left" rowspan="1" colspan="1">ECV</td>
                        <td align="left" rowspan="1" colspan="1">0.442</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Indexed LV mass, g/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">0.442</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                        <td align="left" rowspan="1" colspan="1">Indexed LV mass, g/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">Â·Â·Â·</td>
                        <td align="left" rowspan="1" colspan="1">Â·Â·Â·</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Indexed LVEDV, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">0.401</td>
                        <td align="left" rowspan="1" colspan="1">0.011</td>
                        <td align="left" rowspan="1" colspan="1">Indexed LVEDV, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">0.610</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Indexed LA volume, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">0.307</td>
                        <td align="left" rowspan="1" colspan="1">0.065</td>
                        <td align="left" rowspan="1" colspan="1">Indexed LA volume, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">0.273</td>
                        <td align="left" rowspan="1" colspan="1">0.107</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Indexed RVEDV, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">0.196</td>
                        <td align="left" rowspan="1" colspan="1">0.238</td>
                        <td align="left" rowspan="1" colspan="1">Indexed RVEDV, mL/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">0.305</td>
                        <td align="left" rowspan="1" colspan="1">0.062</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RVEF, %</td>
                        <td align="left" rowspan="1" colspan="1">0.464</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                        <td align="left" rowspan="1" colspan="1">RVEF, %</td>
                        <td align="left" rowspan="1" colspan="1">0.074</td>
                        <td align="left" rowspan="1" colspan="1">0.663</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lateral Eâ², cm/s</td>
                        <td align="left" rowspan="1" colspan="1">0.279</td>
                        <td align="left" rowspan="1" colspan="1">0.086</td>
                        <td align="left" rowspan="1" colspan="1">Lateral Eâ², cm/s</td>
                        <td align="left" rowspan="1" colspan="1">0.069</td>
                        <td align="left" rowspan="1" colspan="1">0.685</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Septal Eâ², cm/s</td>
                        <td align="left" rowspan="1" colspan="1">0.240</td>
                        <td align="left" rowspan="1" colspan="1">0.141</td>
                        <td align="left" rowspan="1" colspan="1">Septal Eâ², cm/s</td>
                        <td align="left" rowspan="1" colspan="1">0.103</td>
                        <td align="left" rowspan="1" colspan="1">0.543</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Mean Eâ², cm/s</td>
                        <td align="left" rowspan="1" colspan="1">0.348</td>
                        <td align="left" rowspan="1" colspan="1">0.030</td>
                        <td align="left" rowspan="1" colspan="1">Mean Eâ², cm/s</td>
                        <td align="left" rowspan="1" colspan="1">0.097</td>
                        <td align="left" rowspan="1" colspan="1">0.568</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Systolic BP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">0.236</td>
                        <td align="left" rowspan="1" colspan="1">0.160</td>
                        <td align="left" rowspan="1" colspan="1">Systolic BP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">0.468</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diastolic BP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">0.163</td>
                        <td align="left" rowspan="1" colspan="1">0.336</td>
                        <td align="left" rowspan="1" colspan="1">Diastolic BP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">0.357</td>
                        <td align="left" rowspan="1" colspan="1">0.032</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MABP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">0.153</td>
                        <td align="left" rowspan="1" colspan="1">0.374</td>
                        <td align="left" rowspan="1" colspan="1">MABP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">0.367</td>
                        <td align="left" rowspan="1" colspan="1">0.030</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34641-ntgp-0004">
                    <fn id="jah34641-note-0006">
                      <p>BP indicates blood pressure; ECV, extracellular volume; LA, left atrial; LV, left ventricular; LVEDV, LV endâdiastolic volume; MABP, mean arterial blood pressure; RVEDV, right ventricular endâdiastolic volume; RVEF, right ventricular ejection fraction.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec id="jah34641-sec-0024">
              <title>Discussion</title>
              <p>Although this study failed to demonstrate a change in absolute ECV over the study period, we have demonstrated that MRA administration significantly affects the rate of ECV expansion in HFâPEF. Thereby, our results suggest potential mechanisms for the diseaseâmodifying effect of spironolactone seen in larger randomized trials.<xref rid="jah34641-bib-0007" ref-type="ref">7</xref>, <xref rid="jah34641-bib-0008" ref-type="ref">8</xref>
</p>
              <sec id="jah34641-sec-0025">
                <title>Therapeutic Effect</title>
                <p>We have demonstrated that MRA administration in HFâPEF leads to a decrease in LV mass, a further antihypertensive effect in a wellâtreated cohort, relative regression of myocardial fibrosis, and significant mass reduction of both the cellular and, possibly more important, the extracellular compartments. These data provide important insights into the mode of action of MRAs in HFâPEF and help explain the potential diseaseâmodifying effects of spironolactone previously reported.<xref rid="jah34641-bib-0007" ref-type="ref">7</xref>, <xref rid="jah34641-bib-0008" ref-type="ref">8</xref>, <xref rid="jah34641-bib-0009" ref-type="ref">9</xref>
</p>
                <p>Previous invasive and noninvasive studies have demonstrated that abnormalities of cardiac relaxation in HFâPEF are associated with increased myocardial fibrosis.<xref rid="jah34641-bib-0014" ref-type="ref">14</xref>, <xref rid="jah34641-bib-0015" ref-type="ref">15</xref> Progressive fibrosis is promoted by elevation of circulating aldosterone levels.<xref rid="jah34641-bib-0027" ref-type="ref">27</xref> In addition, aldosterone antagonism has previously been demonstrated to lead to positive changes in cardiac relaxation, which are associated with change in circulating levels of markers of collagen turnover.<xref rid="jah34641-bib-0009" ref-type="ref">9</xref>, <xref rid="jah34641-bib-0028" ref-type="ref">28</xref> It is likely that the absence of change in biomarkers seen in this study was related to sample size, as the effect of MRAs on markers of collagen turnover are well established.<xref rid="jah34641-bib-0009" ref-type="ref">9</xref>
</p>
                <p>Impaired cardiac relaxation caused by increased myocardial fibrosis leads to elevation of left atrial pressure, in turn leading to elevation of pulmonary pressures and progressive right ventricular dysfunction. Recent studies have demonstrated that myocardial fibrosis and expansion of the extracellular matrix are associated with both poor outcomes and the presence of pulmonary hypertension in HFâPEF.<xref rid="jah34641-bib-0014" ref-type="ref">14</xref>, <xref rid="jah34641-bib-0015" ref-type="ref">15</xref> In a retrospective subgroup analysis of the TOPCAT trial, spironolactone was demonstrated to lead to a reduction in morbidity and mortality in selected patients.<xref rid="jah34641-bib-0006" ref-type="ref">6</xref> In our study, ÎECV was significantly correlated with change in indexed LV mass and change in mean Eâ². This association suggests that the previously observed beneficial effects of spironolactone are likely related to improved passive stiffness because of regression of diffuse myocardial fibrosis and decrease in LV mass.</p>
              </sec>
              <sec id="jah34641-sec-0026">
                <title>Blood Pressure Effect</title>
                <p>Patients in this study underwent 24âhour blood pressure monitoring on enrollment and at completion of the study. Treatment with spironolactone led to a significant decrease in blood pressure versus controls, with an associated decrease in LV mass, despite appropriate blood pressure control at enrollment.</p>
                <p>We are unable to determine if the difference in rate of change in myocardial fibrosis accumulation observed is caused by improved blood pressure control with a decrease in afterload, a direct antifibrotic effect of spironolactone, or a combination of the 2. Alternatively, it has been previously reported that the diuretic effect of some nonneurohormonal antihypertensive agents results in significant change in LV geometry independent of mean blood pressure. However, the relative mass change of the extracellular compartment was greater than the change in myocyte mass, suggesting that the change is not purely caused by decrease in afterload and that spironolactone is exerting a direct tissue effect in HFâPEF.</p>
                <p>Despite normal blood pressure at enrollment, significant regression in LV mass was seen in this study. This suggests that despite blood pressure being within the normal range, further reduction of systolic blood pressure leads to positive cardiac reverse remodeling. Elevated LV mass has previously been shown to be associated with adverse prognosis in hypertension. The benefits of enhanced blood pressure control seen in the SPRINT (Systolic Blood Pressure Intervention Trial)<xref rid="jah34641-bib-0029" ref-type="ref">29</xref> may, in part, be explained by such an effect.</p>
              </sec>
              <sec id="jah34641-sec-0027">
                <title>Future Directions</title>
                <p>Neurohormonal activation, myocardial fibrosis, salt/water retention, and hypertension are all key features of HFâPEF pathophysiological characteristics and are modified by MRAs. We have shown that MRAs lead to demonstrable change in blood pressure and myocardial tissue composition. A decrease in the mass of the extracellular compartment, and fibrosis, is likely to lead to an improvement in passive stiffness. However, this only addresses one aspect of a complex syndrome: active stiffness, abnormalities of ventricularâaortic coupling, and complex systemic abnormalities are not necessarily affected. The HFâPEF cohort is heterogeneous and probably includes multiple pathological conditions and disease manifestations. Further characterization and phenotyping to identify the subgroups that make up the population is essential. Future studies are likely to focus on identifying agents to target impairment of active stiffness and address additional factors specific to the abnormalities underlying different HFâPEF subgroups. In addition, myocardial ECV assessment has now been used to help differentiate between patients with hypertension and HFâPEF and identify those with significant functional limitation.<xref rid="jah34641-bib-0030" ref-type="ref">30</xref> It is possible in future studies that an ECV threshold may be used for study enrollment.</p>
                <p>Although our findings are consistent with prior mechanistic studies, we did not demonstrate a correlation between change in circulating biomarkers of collagen turnover and fibrosis regression or cardiac relaxation. However, prior studies have separately shown that aldosterone antagonism in HFâPEF leads to both; the lack of such an association seen herein may be related to limitation of sample size.</p>
              </sec>
              <sec id="jah34641-sec-0028">
                <title>Limitations</title>
                <p>Although the findings of this study are novel and in line with prior mechanistic studies, there are some important limitations. First, despite the analysis being performed in a blinded manner, this was a nonblinded study without placebo control; consequently, the results need to be confirmed in a larger blinded, placeboâcontrolled, randomized trial.</p>
                <p>The dropout rate of 27% was higher than anticipated, and, as a result, only 41 participants completed the study. Most dropouts were because of withdrawal of consent, caused, in part, by the demanding nature of study protocol. Withdrawal was asymmetric, with 8 in the active treatment group and 3 in the control group. Only 3 withdrawals were directly related to adverse events caused by medication administration, which is in line with prior studies examining the effect of aldosterone antagonists. This suggests that with appropriate monitoring, this class of medication can be used safely in this patient group. Furthermore, although prespecified, it must be recognized that the secondary outcome findings may have occurred by chance.</p>
                <p>The study population included a high percentage of patients with atrial fibrillation when compared with other HFâPEF studies. The reasons for this in our study are not clear; however, although this differs from previously published data, subgroup analysis of the TOPCAT trial suggests that these patients may benefit from spironolactone administration. In addition, the presence of atrial fibrillation may theoretically affect CMR ECV calculation because of variable cycle length. This was not corrected for in this study, and ideally all CMR examinations would be performed in sinus rhythm.</p>
                <p>We excluded patients with diabetes mellitus as a response to initial data from our center, suggesting the presence of ECV expansion in diabetes mellitus with microalbuminemia.<xref rid="jah34641-bib-0021" ref-type="ref">21</xref> This step was taken in an attempt to minimize heterogeneity in the study population as a response to problems with previous HFâPEF studies; however, we recognize this too may limit application of the findings as diabetes mellitus is a frequently encountered comorbidity in populations with HFâPEF.</p>
              </sec>
            </sec>
            <sec id="jah34641-sec-0029">
              <title>Conclusions</title>
              <p>In this study, we have demonstrated that spironolactone decreases the rate of accumulation of myocardial fibrosis in HFâPEF, an abnormality increasingly linked to both its pathophysiological characteristics and prognosis. The masses of both the extracellular and cellular myocardial compartments decreased significantly over the study period and occurred in association with a decrease in blood pressure. Our data and prior studies support that spironolactone has a direct tissue effect on myocardium in HFâPEF, as well as secondary effects caused by further blood pressure modification.</p>
            </sec>
            <sec id="jah34641-sec-0031">
              <title>Sources of Funding</title>
              <p>This study and Dr McDiarmid are funded by a British Heart Foundation (BHF) Project Grant (PG/14/10/30641). Dr Swoboda is funded by a BHF Clinical Fellowship (FS/12/88/29474). Dr Plein is funded by a BHF Personal Chair (CH/16/2/32089) and Program Grant (RG/16/1/32092). Dr Witte holds a National Institute for Health Research (NIHR) Clinician Scientist award. This study was supported by the NIHR Leeds Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.</p>
            </sec>
            <sec id="jah34641-sec-0032">
              <title>Disclosures</title>
              <p>Drs Greenwood and Plein received a research grant from Philips Healthcare. The remaining authors have no disclosures to report.</p>
            </sec>
          </body>
          <back>
            <ack id="jah34641-sec-0030">
              <title>Acknowledgments</title>
              <p>The authors are grateful for the support and assistance of the radiographers (Gavin Bainbridge, Margaret Saysell, Caroline Richmond, and Stephen Mhiribidi), cardiac magnetic resonance imaging (MRI) assistants (Deborah Scarlett and Ann Heald), and cardiac MRI research nurses (Lisa Clark and Fiona Richards), allowing the completion of this project.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah34641-bibl-0001">
              <title>References</title>
              <ref id="jah34641-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0001"><string-name><surname>Ponikowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Voors</surname><given-names>AA</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <string-name><surname>Bueno</surname><given-names>H</given-names></string-name>, <string-name><surname>Cleland</surname><given-names>JF</given-names></string-name>, <string-name><surname>Coayts</surname><given-names>AJS</given-names></string-name>, <string-name><surname>Falk</surname><given-names>V</given-names></string-name>, <string-name><surname>GonzalezâJuanatey</surname><given-names>JR</given-names></string-name>, <string-name><surname>Harjola</surname><given-names>VP</given-names></string-name>, <string-name><surname>Jankowska</surname><given-names>EA</given-names></string-name>, <string-name><surname>Jessup</surname><given-names>M</given-names></string-name>, <string-name><surname>Linde</surname><given-names>C</given-names></string-name>, <string-name><surname>Nihoyannopoulos</surname><given-names>P</given-names></string-name>, <string-name><surname>Parissis</surname><given-names>BP</given-names></string-name>, <string-name><surname>Riley</surname><given-names>JP</given-names></string-name>, <string-name><surname>Rosano</surname><given-names>GM</given-names></string-name>, <string-name><surname>Ruilope</surname><given-names>LM</given-names></string-name>, <string-name><surname>Ruschitzka</surname><given-names>F</given-names></string-name>, <string-name><surname>Rutten</surname><given-names>FH</given-names></string-name>, <string-name><surname>van der Meer</surname><given-names>P</given-names></string-name>. <article-title>2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>2129</fpage>â<lpage>2200</lpage>.<pub-id pub-id-type="pmid">27206819</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0002"><string-name><surname>Borlaug</surname><given-names>BA</given-names></string-name>, <string-name><surname>Paulus</surname><given-names>WJ</given-names></string-name>. <article-title>Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>670</fpage>â<lpage>679</lpage>.<pub-id pub-id-type="pmid">21138935</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0003"><string-name><surname>Cleland</surname><given-names>JG</given-names></string-name>, <string-name><surname>Tendera</surname><given-names>M</given-names></string-name>, <string-name><surname>Adamus</surname><given-names>J</given-names></string-name>, <string-name><surname>Freemantle</surname><given-names>N</given-names></string-name>, <string-name><surname>Polonski</surname><given-names>L</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>J</given-names></string-name>. <article-title>The perindopril in elderly people with chronic heart failure (PEPâCHF) study</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2006</year>;<volume>27</volume>:<fpage>2338</fpage>â<lpage>2345</lpage>.<pub-id pub-id-type="pmid">16963472</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0004"><string-name><surname>Massie</surname><given-names>BM</given-names></string-name>, <string-name><surname>Carson</surname><given-names>PE</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Komajda</surname><given-names>M</given-names></string-name>, <string-name><surname>McKelvie</surname><given-names>R</given-names></string-name>, <string-name><surname>Zile</surname><given-names>M</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>S</given-names></string-name>, <string-name><surname>Donovan</surname><given-names>M</given-names></string-name>, <string-name><surname>Iverson</surname><given-names>E</given-names></string-name>, <string-name><surname>Staiger</surname><given-names>C</given-names></string-name>, <string-name><surname>Ptaszynska</surname><given-names>A</given-names></string-name>. <article-title>Irbesartan in patients with heart failure and preserved ejection fraction</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>2456</fpage>â<lpage>2467</lpage>.<pub-id pub-id-type="pmid">19001508</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0005"><string-name><surname>Liu</surname><given-names>F</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Feng</surname><given-names>X</given-names></string-name>, <string-name><surname>Teng</surname><given-names>Z</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Bin</surname><given-names>J</given-names></string-name>. <article-title>Effects of betaâblockers on heart failure with preserved ejection fraction: a metaâanalysis</article-title>. <source xml:lang="en">PLoS One</source>. <year>2014</year>;<volume>9</volume>:<elocation-id>e90555</elocation-id>.<pub-id pub-id-type="pmid">24599093</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0006"><string-name><surname>Pfeffer</surname><given-names>MA</given-names></string-name>, <string-name><surname>Claggett</surname><given-names>B</given-names></string-name>, <string-name><surname>Assmann</surname><given-names>SF</given-names></string-name>, <string-name><surname>Boineau</surname><given-names>R</given-names></string-name>, <string-name><surname>Anand</surname><given-names>IS</given-names></string-name>, <string-name><surname>Clausell</surname><given-names>N</given-names></string-name>, <string-name><surname>Desai</surname><given-names>AS</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name><surname>Fleg</surname><given-names>JL</given-names></string-name>, <string-name><surname>Gordeev</surname><given-names>I</given-names></string-name>, <string-name><surname>Heitner</surname><given-names>JF</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>EF</given-names></string-name>, <string-name><surname>O'Meara</surname><given-names>E</given-names></string-name>, <string-name><surname>Rouleau</surname><given-names>JL</given-names></string-name>, <string-name><surname>Probstfield</surname><given-names>JL</given-names></string-name>, <string-name><surname>Shaburishvili</surname><given-names>T</given-names></string-name>, <string-name><surname>Shah</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Solomon</surname><given-names>SD</given-names></string-name>, <string-name><surname>Sweitzer</surname><given-names>NK</given-names></string-name>, <string-name><surname>McKinlay</surname><given-names>SM</given-names></string-name>, <string-name><surname>Pitt</surname><given-names>B</given-names></string-name>. <article-title>Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial</article-title>. <source xml:lang="en">Circulation</source>. <year>2015</year>;<volume>131</volume>:<fpage>34</fpage>â<lpage>42</lpage>.<pub-id pub-id-type="pmid">25406305</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0007"><string-name><surname>Pfeffer</surname><given-names>MA</given-names></string-name>, <string-name><surname>Pitt</surname><given-names>B</given-names></string-name>, <string-name><surname>McKinlay</surname><given-names>SM</given-names></string-name>. <article-title>Spironolactone for heart failure with preserved ejection fraction</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>181</fpage>â<lpage>182</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34641-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0008"><string-name><surname>Edelmann</surname><given-names>F</given-names></string-name>, <string-name><surname>Wachter</surname><given-names>R</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>AG</given-names></string-name>, <string-name><surname>KraigherâKrain</surname><given-names>E</given-names></string-name>, <string-name><surname>Colantonio</surname><given-names>C</given-names></string-name>, <string-name><surname>Kamke</surname><given-names>W</given-names></string-name>, <string-name><surname>Duvainage</surname><given-names>A</given-names></string-name>, <string-name><surname>Stahrenberg</surname><given-names>R</given-names></string-name>, <string-name><surname>Durstewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Loffler</surname><given-names>M</given-names></string-name>, <string-name><surname>Dungen</surname><given-names>HD</given-names></string-name>, <string-name><surname>Tschopem</surname><given-names>C</given-names></string-name>, <string-name><surname>HerrmannâLingen</surname><given-names>C</given-names></string-name>, <string-name><surname>Halle</surname><given-names>M</given-names></string-name>, <string-name><surname>Hasenfuss</surname><given-names>G</given-names></string-name>, <string-name><surname>Gelbrich</surname><given-names>G</given-names></string-name>, <string-name><surname>Pieske</surname><given-names>B</given-names></string-name>. <article-title>Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the AldoâDHF randomized controlled trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2013</year>;<volume>309</volume>:<fpage>781</fpage>â<lpage>791</lpage>.<pub-id pub-id-type="pmid">23443441</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0009"><string-name><surname>Deswal</surname><given-names>A</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>P</given-names></string-name>, <string-name><surname>Bozkurt</surname><given-names>B</given-names></string-name>, <string-name><surname>Mann</surname><given-names>DL</given-names></string-name>. <article-title>Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAMâPEF)</article-title>. <source xml:lang="en">J Card Fail</source>. <year>2011</year>;<volume>17</volume>:<fpage>634</fpage>â<lpage>642</lpage>.<pub-id pub-id-type="pmid">21807324</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0010"><string-name><surname>Pitt</surname><given-names>B</given-names></string-name>, <string-name><surname>Zannad</surname><given-names>F</given-names></string-name>, <string-name><surname>Remme</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Cody</surname><given-names>R</given-names></string-name>, <string-name><surname>Castaigne</surname><given-names>A</given-names></string-name>, <string-name><surname>Perez</surname><given-names>A</given-names></string-name>, <string-name><surname>Palensky</surname><given-names>J</given-names></string-name>, <string-name><surname>Wittes</surname><given-names>J</given-names></string-name>; <collab collab-type="authors">Randomized Aldactone Evaluation Study Investigators</collab>
. <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>1999</year>;<volume>341</volume>:<fpage>709</fpage>â<lpage>717</lpage>.<pub-id pub-id-type="pmid">10471456</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0011"><string-name><surname>Zannad</surname><given-names>F</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Krum</surname><given-names>H</given-names></string-name>, <string-name><surname>van Veldhuisen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Swedberg</surname><given-names>K</given-names></string-name>, <string-name><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name><surname>Vincent</surname><given-names>J</given-names></string-name>, <string-name><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Pitt</surname><given-names>B</given-names></string-name>. <article-title>Eplerenone in patients with systolic heart failure and mild symptoms</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>11</fpage>â<lpage>21</lpage>.<pub-id pub-id-type="pmid">21073363</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0012"><string-name><surname>CoelhoâFilho</surname><given-names>OR</given-names></string-name>, <string-name><surname>Shah</surname><given-names>RV</given-names></string-name>, <string-name><surname>Neilan</surname><given-names>TG</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>R</given-names></string-name>, <string-name><surname>Moreno</surname><given-names>H</given-names></string-name>, <string-name><surname>Kwong</surname><given-names>R</given-names></string-name>, <string-name><surname>JeroschâHerold</surname><given-names>M</given-names></string-name>. <article-title>Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone</article-title>. <source xml:lang="en">J Am Heart Assoc</source>. <year>2014</year>;<volume>3</volume>:<elocation-id>e000790</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.114.000790</pub-id>.<pub-id pub-id-type="pmid">24965024</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0013"><string-name><surname>Rommel</surname><given-names>KP</given-names></string-name>, <string-name><surname>von Roeder</surname><given-names>M</given-names></string-name>, <string-name><surname>Latuscynski</surname><given-names>K</given-names></string-name>, <string-name><surname>Oberueck</surname><given-names>C</given-names></string-name>, <string-name><surname>Blazek</surname><given-names>S</given-names></string-name>, <string-name><surname>Fengler</surname><given-names>K</given-names></string-name>, <string-name><surname>Besler</surname><given-names>C</given-names></string-name>, <string-name><surname>Sandri</surname><given-names>M</given-names></string-name>, <string-name><surname>Lucke</surname><given-names>C</given-names></string-name>, <string-name><surname>Gutberlet</surname><given-names>M</given-names></string-name>, <string-name><surname>Linke</surname><given-names>A</given-names></string-name>, <string-name><surname>Schuler</surname><given-names>G</given-names></string-name>, <string-name><surname>Lurz</surname><given-names>P</given-names></string-name>. <article-title>Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>:<fpage>1815</fpage>â<lpage>1825</lpage>.<pub-id pub-id-type="pmid">27081022</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0014"><string-name><surname>Su</surname><given-names>MY</given-names></string-name>, <string-name><surname>Lin</surname><given-names>LY</given-names></string-name>, <string-name><surname>Chang</surname><given-names>CC</given-names></string-name>, <string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Lin</surname><given-names>JL</given-names></string-name>, <string-name><surname>Tseng</surname><given-names>YH</given-names></string-name>. <article-title>CMRâverified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF</article-title>. <source xml:lang="en">JACC Cardiovasc Imaging</source>. <year>2014</year>;<volume>7</volume>:<fpage>991</fpage>â<lpage>997</lpage>.<pub-id pub-id-type="pmid">25240451</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0015"><string-name><surname>Duca</surname><given-names>F</given-names></string-name>, <string-name><surname>Kammerlander</surname><given-names>AA</given-names></string-name>, <string-name><surname>ZotterâTufaro</surname><given-names>C</given-names></string-name>, <string-name><surname>Aschauer</surname><given-names>S</given-names></string-name>, <string-name><surname>Schwaiger</surname><given-names>ML</given-names></string-name>, <string-name><surname>Marzluf</surname><given-names>BA</given-names></string-name>, <string-name><surname>Bonderman</surname><given-names>D</given-names></string-name>, <string-name><surname>Mascherbauer</surname><given-names>J</given-names></string-name>. <article-title>Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study</article-title>. <source xml:lang="en">Circ Cardiovasc Imaging</source>. <year>2016</year>;<volume>9</volume>:<elocation-id>e005277</elocation-id>.<pub-id pub-id-type="pmid">27974408</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0016"><string-name><surname>Williams</surname><given-names>B</given-names></string-name>, <string-name><surname>MacDonald</surname><given-names>TM</given-names></string-name>, <string-name><surname>Morant</surname><given-names>S</given-names></string-name>, <string-name><surname>Webb</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Sever</surname><given-names>P</given-names></string-name>, <string-name><surname>McInnes</surname><given-names>G</given-names></string-name>, <string-name><surname>Ford</surname><given-names>I</given-names></string-name>, <string-name><surname>Cruickshank</surname><given-names>JK</given-names></string-name>, <string-name><surname>Caulfield</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Salsbury</surname><given-names>J</given-names></string-name>, <string-name><surname>MacKenzie</surname><given-names>I</given-names></string-name>, <string-name><surname>Padmanabhan</surname><given-names>S</given-names></string-name>, <string-name><surname>Brown</surname><given-names>MJ</given-names></string-name>. <article-title>Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drugâresistant hypertension (PATHWAYâ2): a randomised, doubleâblind, crossover trial</article-title>. <source xml:lang="en">Lancet</source>. <year>2015</year>;<volume>386</volume>:<fpage>2059</fpage>â<lpage>2068</lpage>.<pub-id pub-id-type="pmid">26414968</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0017"><string-name><surname>Grothues</surname><given-names>F</given-names></string-name>, <string-name><surname>Smith</surname><given-names>GC</given-names></string-name>, <string-name><surname>Moon</surname><given-names>JC</given-names></string-name>, <string-name><surname>Bellenger</surname><given-names>NG</given-names></string-name>, <string-name><surname>Collins</surname><given-names>P</given-names></string-name>, <string-name><surname>Klein</surname><given-names>HU</given-names></string-name>, <string-name><surname>Pennell</surname><given-names>DJ</given-names></string-name>. <article-title>Comparison of interstudy reproducibility of cardiovascular magnetic resonance with twoâdimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>2002</year>;<volume>90</volume>:<fpage>29</fpage>â<lpage>34</lpage>.<pub-id pub-id-type="pmid">12088775</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0018"><string-name><surname>Sado</surname><given-names>DM</given-names></string-name>, <string-name><surname>Flett</surname><given-names>AS</given-names></string-name>, <string-name><surname>Banypersad</surname><given-names>SM</given-names></string-name>, <string-name><surname>White</surname><given-names>SK</given-names></string-name>, <string-name><surname>Maestrini</surname><given-names>V</given-names></string-name>, <string-name><surname>Quarta</surname><given-names>G</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>RH</given-names></string-name>, <string-name><surname>Murph</surname><given-names>E</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>A</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>DA</given-names></string-name>, <string-name><surname>McKenna</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>AM</given-names></string-name>, <string-name><surname>Hausenloy</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Hawkins</surname><given-names>PN</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>PM</given-names></string-name>, <string-name><surname>Moon</surname><given-names>JC</given-names></string-name>. <article-title>Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease</article-title>. <source xml:lang="en">Heart</source>. <year>2012</year>;<volume>98</volume>:<fpage>1436</fpage>â<lpage>1441</lpage>.<pub-id pub-id-type="pmid">22936681</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0019"><string-name><surname>Schelbert</surname><given-names>EB</given-names></string-name>, <string-name><surname>Fridman</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TC</given-names></string-name>, <string-name><surname>Daya</surname><given-names>HA</given-names></string-name>, <string-name><surname>Piehler</surname><given-names>KM</given-names></string-name>, <string-name><surname>Kadakkal</surname><given-names>A</given-names></string-name>, <string-name><surname>Miller</surname><given-names>CA</given-names></string-name>, <string-name><surname>Ugander</surname><given-names>M</given-names></string-name>, <string-name><surname>Maanja</surname><given-names>M</given-names></string-name>, <string-name><surname>Kellman</surname><given-names>P</given-names></string-name>, <string-name><surname>Shah</surname><given-names>D</given-names></string-name>, <string-name><surname>Abebe</surname><given-names>KZ</given-names></string-name>, <string-name><surname>Simon</surname><given-names>MA</given-names></string-name>, <string-name><surname>Quarta</surname><given-names>G</given-names></string-name>, <string-name><surname>Senni</surname><given-names>M</given-names></string-name>, <string-name><surname>Butler</surname><given-names>J</given-names></string-name>, <string-name><surname>Diez</surname><given-names>J</given-names></string-name>, <string-name><surname>Redfield</surname><given-names>MM</given-names></string-name>, <string-name><surname>Gheorghiade</surname><given-names>M</given-names></string-name>. <article-title>Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2017</year>;<volume>2</volume>:<fpage>995</fpage>â<lpage>1006</lpage>.<pub-id pub-id-type="pmid">28768311</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0020"><string-name><surname>Schelbert</surname><given-names>EB</given-names></string-name>, <string-name><surname>Sabbah</surname><given-names>HN</given-names></string-name>, <string-name><surname>Butler</surname><given-names>J</given-names></string-name>, <string-name><surname>Gheorghiade</surname><given-names>M</given-names></string-name>. <article-title>Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics</article-title>. <source xml:lang="en">Circ Cardiovasc Imaging</source>. <year>2017</year>;<volume>10</volume>:<elocation-id>e005619</elocation-id>.<pub-id pub-id-type="pmid">28512159</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0021"><string-name><surname>Swoboda</surname><given-names>PP</given-names></string-name>, <string-name><surname>McDiarmid</surname><given-names>AK</given-names></string-name>, <string-name><surname>Erhayiem</surname><given-names>B</given-names></string-name>, <string-name><surname>Ripley</surname><given-names>DP</given-names></string-name>, <string-name><surname>Dobson</surname><given-names>LE</given-names></string-name>, <string-name><surname>Garag</surname><given-names>P</given-names></string-name>, <string-name><surname>Musa</surname><given-names>TA</given-names></string-name>, <string-name><surname>Witte</surname><given-names>KK</given-names></string-name>, <string-name><surname>Kearney</surname><given-names>MT</given-names></string-name>, <string-name><surname>Barth</surname><given-names>JH</given-names></string-name>, <string-name><surname>Ajjan</surname><given-names>R</given-names></string-name>, <string-name><surname>Greenwood</surname><given-names>JP</given-names></string-name>, <string-name><surname>Plein</surname><given-names>S</given-names></string-name>. <article-title>Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure</article-title>. <source xml:lang="en">J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005539</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.117.005539</pub-id>.<pub-id pub-id-type="pmid">28716801</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="miscellaneous" id="jah34641-cit-0022"><collab collab-type="authors">Excellence NIfHaC</collab>
. <article-title>Chronic heart failure in adults: management (CG108)</article-title>. <year>2010</year> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/Guidance/CG108">https://www.nice.org.uk/Guidance/CG108</ext-link>. Accessed December 1, 2013.</mixed-citation>
              </ref>
              <ref id="jah34641-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="book" id="jah34641-cit-0023"><collab collab-type="authors">Joint Formulary Committee</collab>
. Britain BMAatRPSoG. <source xml:lang="en">British National Formulary</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>BMJ Publishing Group</publisher-name>; <year>2012</year>.</mixed-citation>
              </ref>
              <ref id="jah34641-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0024"><string-name><surname>McDiarmid</surname><given-names>AK</given-names></string-name>, <string-name><surname>Swoboda</surname><given-names>PP</given-names></string-name>, <string-name><surname>Erhayiem</surname><given-names>B</given-names></string-name>, <string-name><surname>Ripley</surname><given-names>DP</given-names></string-name>, <string-name><surname>Kidambi</surname><given-names>A</given-names></string-name>, <string-name><surname>Broadbent</surname><given-names>DA</given-names></string-name>, <string-name><surname>Higgins</surname><given-names>DM</given-names></string-name>, <string-name><surname>Greenwood</surname><given-names>JP</given-names></string-name>, <string-name><surname>Plein</surname><given-names>S</given-names></string-name>. <article-title>Single bolus versus split dose gadolinium administration in extraâcellular volume calculation at 3 Tesla</article-title>. <source xml:lang="en">J Cardiovasc Magn Reson</source>. <year>2015</year>;<volume>17</volume>:<fpage>6</fpage>.<pub-id pub-id-type="pmid">25638228</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0025"><string-name><surname>Rogers</surname><given-names>T</given-names></string-name>, <string-name><surname>Dabir</surname><given-names>D</given-names></string-name>, <string-name><surname>Mahmoud</surname><given-names>I</given-names></string-name>, <string-name><surname>Voigt</surname><given-names>T</given-names></string-name>, <string-name><surname>Schaeffter</surname><given-names>T</given-names></string-name>, <string-name><surname>Nagel</surname><given-names>E</given-names></string-name>, <string-name><surname>Puntmann</surname><given-names>VO</given-names></string-name>. <article-title>Standardization of T1 measurements with MOLLI in differentiation between health and disease: the ConSept study</article-title>. <source xml:lang="en">J Cardiovasc Magn Reson</source>. <year>2013</year>;<volume>15</volume>:<fpage>78</fpage><ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/Guidance/CG108">https://www.nice.org.uk/Guidance/CG108</ext-link><pub-id pub-id-type="pmid">24025486</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0026"><string-name><surname>Kellman</surname><given-names>P</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>JR</given-names></string-name>, <string-name><surname>Xue</surname><given-names>H</given-names></string-name>, <string-name><surname>Ugander</surname><given-names>M</given-names></string-name>, <string-name><surname>Arai</surname><given-names>AE</given-names></string-name>. <article-title>Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method</article-title>. <source xml:lang="en">J Cardiovasc Magn Reson</source>. <year>2012</year>;<volume>14</volume>:<fpage>63</fpage>.<pub-id pub-id-type="pmid">22963517</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0027"><string-name><surname>Weber</surname><given-names>KT</given-names></string-name>. <article-title>Aldosterone in congestive heart failure</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2001</year>;<volume>345</volume>:<fpage>1689</fpage>â<lpage>1697</lpage>.<pub-id pub-id-type="pmid">11759649</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0028"><string-name><surname>Edwards</surname><given-names>NC</given-names></string-name>, <string-name><surname>Ferro</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Kirkwood</surname><given-names>H</given-names></string-name>, <string-name><surname>Chue</surname><given-names>CD</given-names></string-name>, <string-name><surname>Young</surname><given-names>AA</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>PM</given-names></string-name>, <string-name><surname>Steeds</surname><given-names>RP</given-names></string-name>, <string-name><surname>Townend</surname><given-names>JN</given-names></string-name>. <article-title>Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>:<fpage>1505</fpage>â<lpage>1511</lpage>.<pub-id pub-id-type="pmid">21059444</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0029"><string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>JK</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Rocco</surname><given-names>MV</given-names></string-name>, <string-name><surname>Reboussin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CE</given-names></string-name>, <string-name><surname>Kimmel</surname><given-names>PL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names></string-name>, <string-name><surname>Fine</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>AK</given-names></string-name>, <string-name><surname>Ambrosius</surname><given-names>WT</given-names></string-name>. <article-title>A randomized trial of intensive versus standard bloodâpressure control</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>2103</fpage>â<lpage>2116</lpage>.<pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation>
              </ref>
              <ref id="jah34641-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah34641-cit-0030"><string-name><surname>Mordi</surname><given-names>IR</given-names></string-name>, <string-name><surname>Singh</surname><given-names>S</given-names></string-name>, <string-name><surname>Rudd</surname><given-names>A</given-names></string-name>, <string-name><surname>Srinivasan</surname><given-names>J</given-names></string-name>, <string-name><surname>Frenneaux</surname><given-names>M</given-names></string-name>, <string-name><surname>Tzemos</surname><given-names>M</given-names></string-name>, <string-name><surname>Dawson</surname><given-names>DK</given-names></string-name>. <article-title>Comprehensive echocardiographic and cardiac magnetic resonance evaluation differentiates among heart failure with preserved ejection fraction patients, hypertensive patients, and healthy control subjects</article-title>. <source xml:lang="en">JACC Cardiovasc Imaging</source>. <year>2018</year>;<volume>11</volume>:<fpage>577</fpage>â<lpage>585</lpage>.<pub-id pub-id-type="pmid">28823736</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
